Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Pfizer logo
PfizerPFE
$207.62B-0.2%
Cardinal Health logo
Cardinal HealthCAH
$56.69B+13.7%
McKesson logo
McKessonMCK
$88.33B+8.6%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$1.49B+11.3%
Cencora logo
CencoraCOR
$83.81B+13.3%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$11.86B+2.8%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemJune 30, 2026December 31, 2025
Class B common stock, $0.01 par value, 300,000 shares authorized at both June 30, 2026 and December 31, 2025; none issued at both June 30, 2026 and December 31, 2025
Additional paid-in capital545,584571,794
Stockholders’ accumulated deficit(415,087)(535,005)
Accumulated other comprehensive loss(100,666)(110,729)
Total Amneal Pharmaceuticals, Inc. stockholders’ equity (deficiency)33,024(70,794)
Non-controlling interests(535)
Total stockholders’ equity (deficiency)33,024(71,329)
Total liabilities and stockholders’ equity (deficiency)$3,776,348$3,678,280

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s total liabilities & equity?
Amneal Pharmaceuticals, Inc. (AMRX) reported total liabilities & equity of $3.78B in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s total liabilities & equity changed year-over-year?
Amneal Pharmaceuticals, Inc.'s total liabilities & equity increased by 10.3% year-over-year, from $3.42B to $3.78B.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s total liabilities & equity has grown at a -1.7% compound annual growth rate (CAGR), from $4.01B to $3.68B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Amneal Pharmaceuticals, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude